| Debug Stats | ### Total Build Time: 20 ms 24.095 KB CONCEPT_NAME gt=1 ms Completed: 1 ms rowSize= 388 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=NONE 1 ms Completed: 1 ms rowSize= 0 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=1 ms Completed: 1 ms rowSize= 106 bytesCONCEPT_GENES gt=11 ms Completed: 11 ms rowSize= 22.363 KBCONCEPT_XREFS gt=6 ms Completed: 6 ms rowSize= 1.179 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Genes (13)
Species:
human : 13 | |
| Human | BACE1 | 23621 | beta-site APP-cleaving enzyme 1 | Activity levels are increased in brain regions affected by amyloid deposition and remain increased despite significant neuronal and synaptic loss in Alzheimer disease | | Human | ITM2B | 9445 | integral membrane protein 2B | Expression of wild-type human ITM2B reduces cerebral amyloid beta deposition in a mouse model of Alzheimer's disease | | Human | OSMR | 9180 | oncostatin M receptor | Localized amyloid deposition | | Human | TGFBI | 7045 | transforming growth factor, beta-induced, 68kDa | This unusual case of an individual with the R124C mutation of TGFBI gene without histopathological evidence of amyloid deposition TGFBI gene mutations were not identified in a series of patients with polymorphic corneal amyloid deposition | | Human | SNCA | 6622 | synuclein, alpha (non A4 component of amyloid precursor) | The constant and abundant amyloid beta x-42 deposition in sporadic dementia with Lewy bodies suggests that alpha-synucleinopathy is also promoted by amyloid precursor protein dysfunction | | Human | NOS2 | 4843 | nitric oxide synthase 2, inducible | The amyloid-beta protein precursor NOS2(-/-) bigenic mice progress from production and amyloid deposition to hyperphosphorylated normal mouse tau at Alzheimer's disease associated epitopes--REVIEW iNOS seems to be a major instigator of beta-amyloid deposition and disease progression in mice with Alzheimer's-like disease resulting from transgenic expression of mutant human beta-amyloid precursor protein and presenilin-1 | | Human | MAPT | 4137 | microtubule-associated protein tau | mature, parkin null, over-expressing human mutated tau (PK(-/-)/Tau(VLW)) mice have altered behaviour and dopamine neurotransmission, tau pathology in brain and amyloid deposition in brain and peripheral organs | | Human | LYZ | 4069 | lysozyme | Data suggest that partial unfolding is an intrinsic property of the human lysozyme structure, and suggest that the readiness with which it occurs is a critical feature determining whether or not amyloid deposition occurs in vivo | | Human | LHB | 3972 | luteinizing hormone beta polypeptide | LH modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition | | Human | CST3 | 1471 | cystatin C | Using transgenic mice expressing human cystatin C (encoded by CST3), study shows that cystatin C binds soluble amyloid-beta peptide and inhibits cerebral amyloid deposition in amyloid-beta precursor protein (APP) transgenic mice Accumulating data suggest involvement of cystatin C in the pathogenic processes leading to amyloid deposition in cerebral vasculature and most significantly to cerebral hemorrhage in patients with cerebral amyloid angiopathy {REVIEW} Study shows that overexpression of human cystatin C in brains of APP-transgenic mice reduces cerebral amyloid-beta deposition and that cystatin C binds amyloid-beta and inhibits its fibril formation | | Human | CD36 | 948 | CD36 molecule (thrombospondin receptor) | CD36 has a role in beta-amyloid deposition but not with Alzheimer's disease | | Human | APP | 351 | amyloid beta (A4) precursor protein | Data demonstrate severe amyloid deposition in mammary glands of familial amyloid polyneuropathy patients The amyloid-beta protein precursor/ nitric oxide synthase 2 inducible bigenic mice progress from production and amyloid deposition to hyperphosphorylated normal mouse tau at Alzheimer's disease associated epitopes--REVIEW The posterior cingulate is preferentially vulnerable to both effects of transgene in the PDAPP mouse, and both are independent of amyloid deposition beta-amyloid deposition levels in brain correlate with CD36 expression independent of the occurrence of Alzheimer's disease glypican-1 interacts with polymerized Abeta in detergent-insoluble glycosphingolipid-enriched domains, resulting not only in amyloid deposition in senile plaques of AD brain, but also in accelerating neuronal cell death in response to stress and Abeta processing of amyloid-beta precursor protein and amyloid-beta deposition are modulated by luteinizing hormone | | Human | APOE | 348 | apolipoprotein E | Epsilon3-haplotypes containing the promoter allele -219T were associated with reduced amyloid deposition and reduced risk of neuropathologically verified Alzheimer disease as compared to epsilon3-haplotypes containing -219G Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity apolipoprotein e4 allele works through amyloid deposition and subsequent tangle formation to cause cognitive impairment |
|
